Grace Therapeutics, Inc. (GRCE)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Mar 31
Key ratios (FY2025)
-14.4%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $196.0K | — | — | — |
| Cost of Revenue | — | — | — | $0 | $76.0K | — | — | — |
| Operating Income | -$16.68M | -$12.85M | -$52.16M | -$15.59M | -$16.42M | -$24.44M | -$34.41M | — |
| Net Income | -$9.57M | -$12.85M | -$42.43M | -$9.82M | -$19.68M | -$25.51M | -$39.37M | — |
| EPS (Diluted) | $-0.79 | $-1.35 | $-5.71 | $-0.27 | — | — | — | — |
| Total Assets | $71.99M | $73.30M | $79.12M | $128.62M | $62.46M | $22.85M | $36.90M | — |
| Total Liabilities | $5.38M | $11.56M | $11.17M | $20.35M | $6.80M | $9.86M | $25.85M | — |
| Shareholders' Equity | $66.61M | $61.74M | $67.95M | $108.27M | $55.66M | $12.99M | $11.04M | $7.19M |
| Cash & Equivalents | $22.13M | $23.00M | $27.88M | $30.34M | $50.94M | $14.24M | $16.87M | $6.42M |
| Operating Cash Flow | -$14.90M | -$12.33M | -$15.91M | -$17.23M | -$14.32M | -$22.95M | — | — |
| Shares Outstanding | 12.09M | 9.53M | 7.44M | 36.84M | — | — | — | — |